Inversago Pharma Inc.: Inversago Pharma Raises $95 million CAD in Series C Financing

Series C financing led by NEA Provides advancement of INV-202 Phase 2 clinical trial in Diabetic Kidney Disease in Q4 Inversago Pharma Inc. ("Inversago"), a clinical stage biotech company with a unique

Related Keywords

Germany ,Montreal ,Quebec ,Canada ,Netherlands ,Singapore ,Canadian ,Inversago Pharma ,Kostenloser Wertpapierhandel ,Ed Mathers ,Company Series ,Rd Fund ,Enterprise Associates Inc ,Forbion Growth Opportunities Fund ,Enterprise Associates ,Forbion Ventures Fund Iv ,Inversago Pharma Inc ,Diabetic Kidney Disease ,New Enterprise Associates ,Growth Opportunities Fund ,Amgen Ventures ,Ventures Fund ,Genesys Capital ,Mare Bioinnovations ,Chief Executive Officer ,Diabetic Kidney Diseases ,General Partner ,Forbion Growth ,United Nations Principles ,Diabetic Nephropathy ,Non Alcoholic Steatohepatitis ,Progressive Fibrosis Interstitial Lung Disease ,Idiopathic Pulmonary Fibrosis ,Executive Officer ,Inversago ,Dharma ,Raises ,Billion ,Series ,Financing ,